罗哌卡因两种脂质体改良制剂的临床前评价
本研究在大鼠坐骨神经阻滞模型和兔药代动力学模型中,评价了含罗哌卡因的脂质体新制剂(LMVV及LMVV/LUV复合系统)的麻醉持续时间、药代动力学和组织反应。结果显示所有脂质体制剂均延长了感觉阻滞时间和镇痛持续时间,且未对局部组织产生显著毒性;LMVV能延缓罗哌卡因释放,降低全身暴露。
要点
- 脂质体罗哌卡因制剂较普通溶液延长感觉阻滞和镇痛时间。
- LMVV制剂可延缓释放,降低罗哌卡因全身暴露。
- 组织学评估中脂质体制剂局部毒性低于利多卡因10%阳性对照。
核心结论
- 含0.75%罗哌卡因的脂质体制剂能改变药代动力学并延长麻醉时间,且不引起显著局部组织毒性。
研究设计与样本
- Wistar大鼠(每组n=6)接受坐骨神经阻滞(0.4 mL)比较6种罗哌卡因制剂。
- 大鼠(n=6)足底切口模型评估机械性痛觉过敏。
- 新西兰白兔(n=6)接受坐骨神经阻滞(3 mL)后采血测定罗哌卡因血浆浓度。
主要发现
- 所有脂质体制剂的感觉阻滞持续时间和强度均长于普通罗哌卡因溶液(P < .05)。
- 足底切口后脂质体制剂镇痛时间更长(P < .05)。
- LMVVRVC0.75%的达峰时间和平均驻留时间高于其余含0.75%罗哌卡因的制剂(P < .05)。
- 组织学评估中利多卡因10%阳性对照的毒性高于所有制剂(P < .05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our research group has recently developed liposomes with ionic gradient and in a combined manner as donor and acceptor vesicles containing ropivacaine (RVC; at 2% or 0.75%). Looking for applications of such novel formulations for postoperative pain control, we evaluated the duration of anesthesia, pharmacokinetics, and tissue reaction evoked by these new RVC formulations. METHODS: The formulations used in this study were large multivesicular vesicle (LMVV) containing sodium acetate buffer at pH 5.5 or in a combined manner with LMVV as donor and large unilamellar vesicles (LUVs) as acceptor vesicles with an external pH of 7.4. Wistar rats were divided into 6 groups (n = 6) and received sciatic nerve block (0.4 mL) with 6 formulations of RVC (LMVVRVC0.75%, LMVV/LUVRVC0.75%, LMVVRVC2%, LMVV/LUVRVC2%, RVC 0.75%, and RVC 2%). To verify the anesthetic effect, the animals were submitted to the pain pressure test and the motor block was also monitored. Histopathology of the tissues surrounding the sciatic nerve region was also assessed 2 and 7 days after treatment. Rats (n = 6) were submitted to a hind paw incision, and mechanical hypersensitivity was measured via the withdrawal response using von Frey filaments after injection of the 6 formulations. Finally, New Zealand white rabbits (n = 6) received sciatic nerve block (3 mL) with 1 of the 6 formulations of RVC. Blood samples were collected predose (0 minutes) and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, 480, and 540 minutes after injection. RVC plasma levels were determined using a triple-stage quadrupole mass spectrometer. RESULTS: Duration and intensity of the sensory block were longer with all liposomal formulations, when compared to the plain RVC solution (P < .05). Histopathological evaluation showed greater toxicity for the positive control (lidocaine 10%), when compared to all formulations (P < .05). After the hind paw incision, all animals presented postincisional hypersensitivity and liposomal formulations showed longer analgesia (P < .05). LMVVRVC0.75% presented higher time to reach maximum concentration and mean residence time than the remaining formulations with RVC 0.75% (P < .05), so LMVV was able to reduce systemic exposure of RVC due to slow release from this liposomal system. CONCLUSIONS: All new liposomal formulations containing 0.75% RVC were able to change the pharmacokinetics and enhance anesthesia duration due to slow release of RVC from liposomes without inducing significant toxic effects to local tissues.
引用
- Rennó CC, Papini JZB, Cereda CMS, et al. Preclinical Evaluation of Ropivacaine in 2 Liposomal Modified Systems. Anesth Analg. 2019. PMID: 30303863. doi:10.1213/ANE.0000000000003837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。